Apyx Medical Corp (APYX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Apyx Medical Corporation is an advanced energy technology company specializing in Helium Plasma Platform Technology, marketed as Renuvion (cosmetic surgery) and J-Plasma (hospital surgical). The company operates two reportable segments: Advanced Energy and OEM (Original Equipment Manufacturer).
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Sales | $12.15 million | $22.39 million | $13.57 million | $25.71 million |
| Gross Profit | $7.49 million | $13.44 million | $9.28 million | $16.85 million |
| Gross Margin | 61.7% | 60.0% | 68.4% | 65.5% |
| Net Loss (Stockholders) | $(6.56) million | $(14.13) million | $(0.99) million | $(4.48) million |
| Loss Per Share (Basic/Diluted) | $(0.19) | $(0.41) | $(0.03) | $(0.13) |
| Cash & Equivalents | $32.68 million | As of June 30, 2024 | ||
| Long-Term Debt (Net) | $33.63 million | As of June 30, 2024 | ||
| Operating Cash Flow | $(10.67) million | $(6.73) million | YTD 2023 |
Material Changes vs. Prior Period
- Revenue Decline: Total sales decreased 10.5% in Q2 and 12.9% YTD compared to 2023. The Advanced Energy segment saw a 16.7% Q2 decline driven by lower generator sales due to economic uncertainty in the aesthetic capital equipment market. This was partially offset by a 29.0% increase in OEM sales.
- Margin Compression: Gross margins declined from 68.4% to 61.7% in Q2. Management attributes this to a sales mix shift toward the lower-margin OEM segment and a higher proportion of international sales within the Advanced Energy segment.
- Increased Losses: Net loss widened significantly to $6.56 million in Q2 2024 from $0.99 million in Q2 2023. This was driven by higher operating expenses (specifically professional services and interest) and lower gross profit.
- Interest Expense: Interest expense increased to $1.43 million in Q2 2024 from $0.54 million in Q2 2023, reflecting the higher interest rate (12.3% at June 30, 2024) on the Perceptive Credit Agreement.
Outlook, Risks, and Contingencies
- Debt Covenants: The company must maintain minimum trailing twelve-month net revenue targets for its Advanced Energy segment ($41.6 million for 2024) and a minimum cash balance of $3 million. As of June 30, 2024, the company was in compliance, but continued compliance depends on meeting forecasted revenues.
- Litigation: The company faces multiple product liability lawsuits regarding off-label use and marketing of Renuvion. Management has accrued $1.45 million for prior cases and $1.30 million for new cases filed in March 2024. While management believes they have meritorious defenses, costs could materially impact financials if insurance coverage is disputed or exceeded.
- Liquidity: Cash decreased by $11.0 million in the first half of 2024. The company has a $7.5 million delayed draw loan available until December 31, 2024, contingent on revenue targets. Management anticipates continued losses and may require additional financing.
- Market Trends: Management notes that GLP-1 weight loss drugs may initially reduce liposuction procedures but could drive long-term demand for body contouring (Renuvion's primary use case) to address loose skin.
Investor Verification Checklist
- Covenant Compliance: Verify if the company meets the $41.6 million Advanced Energy revenue target for the trailing twelve months ending June 30, 2024, to avoid default on the Perceptive Credit Agreement.
- Litigation Exposure: Monitor updates on product liability lawsuits, specifically regarding insurance carrier coverage disputes and potential deductibles that could exceed current accruals.
- Cash Burn Rate: Assess the sustainability of the current cash position ($32.7 million) given the operating cash burn of $10.7 million in the first half of the year.
- Revenue Mix: Track the ratio of Advanced Energy (high margin) vs. OEM (lower margin) sales to understand future margin trajectory.